MedPath

To calculate efficacy and safety of LDV/SOF to HCV genotype 2, Phase 3b randomised non-blinded multiceter trial.

Not Applicable
Conditions
HCV genotype 2
Registration Number
JPRN-UMIN000022566
Lead Sponsor
Shinshu University of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
4
Inclusion Criteria

Not provided

Exclusion Criteria

HCC

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
SVR with 12 week after treatment
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath